Matthew Griffin

AstraZeneca (South Korea) — South Korea

Medicine · Health Sciences

28h-index4.9kcitations207works7.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(62), Astrophysics and Star Formation Studies(41), Cytokine Signaling Pathways and Interactions(36), Stellar, planetary, and galactic studies(34), Astronomy and Astrophysical Research(28)

Publications206 total

<i>Herschel</i> Gould Belt Survey in Taurus – II. A census of dense cores and filaments in the TMC1 region
Monthly Notices of the Royal Astronomical Society·2024· 9 citedOpen Access
1750: Hypofractionated radiotherapy for early larynx cancer: 5-year outcomes from a single centre
Radiotherapy and Oncology·2024
Quantitative evaluation of <scp>trastuzumab deruxtecan</scp> pharmacokinetics and pharmacodynamics in mouse models of varying degrees of <scp>HER2</scp> expression
CPT Pharmacometrics & Systems Pharmacology·2024· 12 citedOpen Access
Supplementary Table S6 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S14 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S5 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S12 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Data from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S2 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Table S4 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S9 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S14 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S1 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Table S6 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S4 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S1 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S3 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S13 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S10 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S2 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
page 1 of 11Next →

Frequent Co-authors

D. Scott(12), M. Vaccari(10), P. A. R. Ade(10), J. Glenn(9), L. Spinoglio(9), D. L. Clements(9), P. G. Martin(8), M. Halpern(8), S. Pezzuto(7), D. Farrah(7), Seb Oliver(7), J. M. Kirk(6), F. Motte(6), L. Olmi(6), N. Schneider(6), Peter Hargrave(6), C. D. Dowell(6), C. P. Pearson(6), Asantha Cooray(6), J. J. Bock(6)